The time from admission to anti-tuberculosis therapy was 4.5 ± 2.0 days. All 85 patients with ARDS were prescribed anti-tuberculosis medication consisting of isoniazid, rifampicin, ethambutol, and pyrazinamide. Mechanical ventilation was necessary in all 85 patients. Thirty-eight patients(44.7%) required invasive mechanical ventilation while the rest were given non-invasive mechanical ventilation with BiPAP. Mean duration of mechanical ventilation was 8.5 ± 3.0 days with ICU mortality of 47.1%. Thirty-five patients (41.2%) received glucocorticoid therapy (methylprednisolone:80 mg/day) intravenously for a maximum of 5 days when anti-tuberculosis therapy was started. The use of glucocorticoids was associated with a mortality of 22.9% (8/35) compared with 76.0% (38/50) in those who were not treated with glucocorticoids. Comparison between patients with miliary TB developing ARDS and patients with miliary TB alone are shown in Table 2 . Comparison between survivors and non-survivors of ARDS patients are shown in Table 3 . Duration of time to diagnosis, time from diagnosis to mechanical ventilation, and time from admission to anti-tuberculosis therapy were significantly shorter in survivors than non-survivors. Also, DM, ALT, AST, Ddimer, hemoglobin, and albumin showed significant difference between the survivor group and non-survivor group. The 3 pregnant patients underwent termination of pregnancy, one of whom died of respiratory failure.